Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

COTTONE, Mario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.243
EU - Europa 5.829
AS - Asia 4.664
SA - Sud America 655
AF - Africa 155
OC - Oceania 26
Continente sconosciuto - Info sul continente non disponibili 7
Totale 22.579
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.025
SG - Singapore 1.745
RU - Federazione Russa 1.330
CN - Cina 1.136
IT - Italia 986
UA - Ucraina 773
DE - Germania 636
BR - Brasile 502
FI - Finlandia 492
HK - Hong Kong 472
VN - Vietnam 433
GB - Regno Unito 385
PL - Polonia 317
IE - Irlanda 300
FR - Francia 235
JP - Giappone 224
IN - India 136
CA - Canada 135
SE - Svezia 116
KR - Corea 99
BD - Bangladesh 73
NL - Olanda 51
MX - Messico 48
AR - Argentina 43
BE - Belgio 43
IQ - Iraq 42
TR - Turchia 39
CI - Costa d'Avorio 38
ES - Italia 38
PK - Pakistan 38
MY - Malesia 35
ZA - Sudafrica 32
RO - Romania 30
VE - Venezuela 29
UZ - Uzbekistan 26
AU - Australia 25
MA - Marocco 22
EC - Ecuador 21
SA - Arabia Saudita 20
AE - Emirati Arabi Uniti 19
ID - Indonesia 19
CH - Svizzera 17
EG - Egitto 17
PY - Paraguay 17
CL - Cile 15
AT - Austria 14
CO - Colombia 14
PH - Filippine 14
JO - Giordania 12
KE - Kenya 12
RS - Serbia 11
CR - Costa Rica 9
IL - Israele 9
NP - Nepal 9
BG - Bulgaria 8
GR - Grecia 8
LB - Libano 8
LT - Lituania 8
TN - Tunisia 8
TW - Taiwan 7
DZ - Algeria 6
GE - Georgia 6
IR - Iran 6
NG - Nigeria 6
PA - Panama 6
UY - Uruguay 6
AL - Albania 5
AZ - Azerbaigian 5
BO - Bolivia 5
JM - Giamaica 5
KG - Kirghizistan 5
PT - Portogallo 5
BY - Bielorussia 4
CZ - Repubblica Ceca 4
EU - Europa 4
KZ - Kazakistan 4
BH - Bahrain 3
ET - Etiopia 3
HU - Ungheria 3
LK - Sri Lanka 3
NO - Norvegia 3
PE - Perù 3
PS - Palestinian Territory 3
QA - Qatar 3
SN - Senegal 3
TT - Trinidad e Tobago 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
BB - Barbados 2
BW - Botswana 2
CM - Camerun 2
DO - Repubblica Dominicana 2
EE - Estonia 2
KH - Cambogia 2
MM - Myanmar 2
TH - Thailandia 2
BA - Bosnia-Erzegovina 1
BM - Bermuda 1
BS - Bahamas 1
CY - Cipro 1
Totale 22.562
Salva come PNG Salva come JPEG
Città #
Ashburn 1.288
Singapore 1.211
Fairfield 1.141
Woodbridge 876
Chandler 657
Houston 635
San Jose 578
Wilmington 469
Hong Kong 458
Jacksonville 439
Ann Arbor 438
Seattle 424
Cambridge 387
Dublin 299
Zgierz 274
Moscow 227
Palermo 218
Tokyo 218
Medford 210
Santa Clara 210
Frankfurt am Main 204
Beijing 188
Nanjing 161
Council Bluffs 156
Los Angeles 154
Princeton 139
Ho Chi Minh City 132
Altamura 126
Lauterbourg 120
Tulsa 109
Hanoi 108
Des Moines 104
Dearborn 91
Lawrence 89
New York 86
Boardman 79
Dallas 77
San Diego 73
Hefei 71
Munich 71
Montréal 61
Mcallen 58
Buffalo 54
Milan 54
Shenyang 52
Helsinki 49
Nanchang 47
Chicago 44
Venice 42
Brussels 41
Kumar 41
London 40
São Paulo 40
The Dalles 40
Abidjan 38
Ludwigshafen am Rhein 38
Seongnam 37
Tianjin 37
Omaha 36
Jiaxing 34
Phoenix 33
Redwood City 30
Atlanta 28
Hebei 28
Changsha 27
Saint Petersburg 26
Amsterdam 25
Jinan 23
Auburn Hills 22
Da Nang 22
Guangzhou 21
Orem 21
Rome 21
San Paolo di Civitate 21
Warsaw 21
Columbus 20
Johannesburg 20
City of London 19
Haiphong 19
Kuala Lumpur 19
Montreal 19
Tashkent 19
Chennai 18
Verona 18
Nuremberg 17
Rio de Janeiro 17
San Mateo 17
Brooklyn 16
San Francisco 16
Shanghai 16
Washington 16
Manchester 15
Orange 14
Pune 14
Zhengzhou 14
Denver 13
Quito 13
Falls Church 12
Lanzhou 12
Poplar 12
Totale 14.652
Salva come PNG Salva come JPEG
Nome #
NUTRITION, MALNUTRITION AND DIETARY INTERVENTIONS IN INFLAMMATORY BOWEL DISEASE 563
Prurigo nodularis of Hyde treated with low-dose thalidomide. 352
Incidence of Crohn's disease and Card 15 mutation in a small township in Sicily 244
Physicians' Knowledge and Application of Immunization Strategies in Patients with Inflammatory Bowel Disease: A Survey of the Italian Group for the Study of Inflammatory Bowel Disease 232
An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C 232
Severe acute colitis associated with CMV:a prevalence study 230
Cyclosporine or infliximab as rescue therapy in severe 2 refractory ulcerative colitis: Early and long-term data 3 from a retrospective observational study 227
Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis 224
An Unusual Presentation of Zollinger-Ellison Syndrome 223
A. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. 223
Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease 223
Budesonide MMX and mesalamine to induce remission in patients with ulcerative colitis 222
Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. 221
Clinical and endoscopic presentation of primary gastric lymphoma:a multicenter study 213
Frequency of NOD2/CARD15 variants in both sporadic and familial cases of Crohn's disease across Italy. An Italian Group for Inflammatory Bowel Disease study 213
EFFICACY AND SAFETY OF ENDOSCOPIC BALLOON DILATION OF SYMPTOMATIC INTESTINAL CROHN'S DISEASE STRICTURES 213
Postoperative maintenance therapy for inflammatory bowel disease 212
Infliximab and ulcerative colitis 211
Beclomethasone dipropionate in Crohn's ileitis: A randomised, double-blind trial. 209
Heart failure and anti tumor necrosis factor-alpha in systemic chronic inflammatory diseases 209
JC Virus, Helicobacter pylori, and Oesophageal Achalasia: Preliminary Results from a Retrospective Case-Control Study 207
Systematic review: macrophage activation syndrome in inflammatory bowel disease 204
Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in post-operative Crohn's disease 203
Efficacy and safety of endoscopic balloon dilation of symptomatic intestinal Crohn's disease strictures. 200
A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients with Crohn's Disease: Real-Life Data from the Sicilian Network for Inflammatory Bowel Disease 198
The frame.shift mutation of the NOD2/Card15 gene is significantly increased in ulcerative colitis: an IG-IBD study 197
Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn's disease. 197
The role of portal vein thrombosis in the clinical course of inflammatory bowel diseases: report on three cases and review of the literature. 197
A rare case of ulcerative proctitis associated with type B lymphomatoid papulosis and superimposed human cytomegalovirus infection. 196
Complete clinical remission after high dose immune suppression and autologous hematopoietic stem cell transplantation in severe Crohn's disease refractory to immunosuppressive and immunomodulator therapy 194
An unusual presentation of T-lymphoma in a Crohn's 4 disease patient treated with combo therapy: We are 5 willing to take a risk of serious adverse events for a 6 doubtful benefit? 192
Six year adalimumab efficacy in steroid-dependent Crohn's disease patients: A prospective single-center real life study 192
COLORECTAL CANCER IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: PRELIMINARY RESULTS FROM AN ONGOING CASE-CONTROL STUDY 190
Oral lichen planus after certolizumab pegol treatment in a patient with Crohn's disease 189
Toxic megacolon and human Cytomegalovirus in a series of severe ulcerative colitis patients 189
Radiologia e malattia celiaca dell'adulto 188
Clinical course of ulcerative colitis 188
MINIMIZING INFLIXIMAB TOXICITY IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE 186
Cytomegalovirus disappearance after treatment for refractory ulcerative colitis in 2 patients treated with infliximab and 1 patient with leukapheresis 186
Probiotics, prebiotics and symbiotics in inflammatory bowel diseases: state-of-the-art and new insights 184
Calprotectin in the prediction of endoscopic post-surgical recurrence in CD 183
Leucocytapheresis in patients with moderate severe steroid dependant Ulcerative Colitis:clinical response without endoscopic response 183
THE ROLE OF CARD15 MUTATIONS AND SMOKING IN THE COURSE OF DISEASE IN A MEDITERRANEAN AREA 183
Antibiotic treatment of Crohn's disease:results of a multicentre double blind randomized placebo controlled trial with Rifamixin 182
Cancer in Crohn's Disease patients treated with infliximab: A long-term multicenter matched pair study 182
CLINICAL COURSE OF SEVERE COLITIS: A COMPARISON BETWEEN CROHN'S DISEASE AND ULCERATIVE COLITIS. 182
Crohn's disease:a comparative prospective study of transabdominal ultrasonography,small intestine contrastultrasonography and small bowel enema 181
Infliximab in the treatment of Crohn's disease :predictors of response in an Italian multicenter open study 180
Methodological problems in RCTs on IBD 177
A real life comparison of the efficacy of adalimumab versus golimumab in moderate-to-severe ulcerative colitis. A multicenter experience from the sicilian network for inflammatory bowel disease (SN-IBD) 176
Long term follow-up in an incident cohort of 583 pts with CD 174
CA-19 to rule out Pancreatic or Biliary Cancer among patients with cholestasis:an unsuitable ? 174
COULD JC VIRUS PROVOKE METASTASIS IN COLON CANCER? 171
Oral valganciclovir for coloni c dilatation in ulcerative colitis associated with Human cytomegalovirus infection 171
The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound 170
IL-23R determines susceptibility in Crohn's disease in a Mediterranean area 170
Infliximab, azathioprine or combination therapy in the treatment of active Crohn's disease. 170
ATG16L1 contribution to Crohn's disease risk in Sicily 168
Burden of Crohn's disease: economics and quality of life aspects in Italy. 167
Tofacitinib in active ulcerative colitis 165
Cancer in Infliximab-treated or untreated crohn's disease patients:a 2 years longer follow-up from a multicenter matched pair study 164
Improving patients Qol:how the success of treatment can improve workability 163
Cytomegalovirus and Inflammmatory bowel disease:is there a link ? 163
Infliximab to treat Crohn's disease: an update 163
Unusual perforation after balloon dilation in a Crohn's disease patient:report of a case 162
Natural history of cytomegalovirus infection in a cohort of patients diagnosed with moderate severe ulcerative colitis 161
Infliximab prevents Crohn's disease recurrence after ileal resection. 161
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. 161
Infliximab in moderate to severe sateroid dipendent or refractory severe ulcerative colitis:short term results of 21 case treated 160
Over-expression of paneth cell-derived anti-microbial peptides in the gut of patients with ankylosing spondylitis and subclinical intestinal inflammation. 160
Methodology for high-quality studies on course and prognosis of inflammatory bowel disease. 158
Severe acute colitis associated with citomegalovirus 157
Radiofrequency thermal ablation vs percutaneous ethanol injection for small hcc in cirrhosis:metanalysis of randomized controlled trials 157
Ultrasound in Crohn's disease 156
A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis. 156
Appropriateness of immunosupprerssive drugs in inflammatory bowel disease assessed by RAND method :Italian group for IBD position statement 155
Is 5-ASA Still the Treatment of Choice for Ulcerative Colitis? 155
efficacy and safety of endoscopic ballon dilatation of symptomatic gastrointestinal Crohn's disease strictures 153
Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. 152
a meta-analysis of the placebo rate of clinical relapse and severe endoscopic recurrence in post-operative maintenance therapy in Crohn's disease 151
Adalimumab in steroid-dependent Crohn's disease patients: Prognostic factors for clinical benefit 151
VALIDATION OF A MODIFIED MODEL OF TNBS-INDUCED COLITIS IN RATS. HOW TO INDUCE A CHEMICAL COLITIS IN RATS. 151
Investigational agents for Crohn's disease. 148
Psychopharmacology treatment and psychological interventions in irritable bowel syndromel 148
The sicilian network for inflammatory bowel disease (SN-IBD): preliminary data on efficacy of biological therapy. 148
The role of NOD2/CARD15 mutation and smoking in the course of Crohn's disease in a Mediterranean area 147
NEWLY DIAGNOSED NEOPLASIA IN CROHN DISESE PATIENTS TREATED WITH INFLIXIMAB;A 1 YEAR LONGER FOLLOW UP FROM A MULTICENTER MATCHED PAIR STUDY 147
Smoking therapy may be an extreme cure in exsmokers with steroid-dependent and resistant ulcerative colitis. 147
Infliximab in the treatment of steroid resistant dependant and fistulating crohn's disease:an analysis of predictors of response in an italian multicenter open study in 573 pts 146
NOD2/CARD15 FREQUENCY IN CROHN'DISEASE IN SICILY:AN EPIDEMIOLOGICAL STUDY 146
randomized clinical trials in perianal disease. 146
Early postoperative recurrence of severe crohn's disease, with colonic involvement and associated human cytomegalovirus infection, treated with oral valganciclovir and adalimumab. 145
Intestinal permeability and Genetic determinants in patients,first degree relatives,and controls in a High incidence area's of Crohn's disease in Southern Italy 143
Natural history of Cytomegalovirus infection diagnosed with moderate-severe ulcerative colitis 142
Le malattie infiammatorie dell'intestino 141
Marked impact of IL28B genotype in the natural clearance of hepatitis C virus in patients with haemoglobinopathies. 141
Occul Hepatitis B and infliximab induced HBV reactivation 137
Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use. 137
PREVALENCE OF CARD15/NOD2 MUTATIONS IN SICILIAN POPULATION 136
Biologic therapies versus conventional therapies. A series of Crohn’s disease patients: “a pair-matched study” 135
Totale 18.332
Salva come PNG Salva come JPEG
Categoria #
all - tutte 77.195
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 77.195
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021377 0 0 0 0 0 0 0 0 0 0 171 206
2021/20221.472 62 376 21 51 43 54 85 67 162 199 84 268
2022/20231.900 202 365 35 185 242 260 71 172 245 12 91 20
2023/2024781 46 145 39 53 91 150 75 34 2 54 32 60
2024/20252.017 49 101 101 230 88 77 109 147 148 216 252 499
2025/20267.825 416 228 421 589 736 1.149 1.072 873 567 1.544 230 0
Totale 22.870